Cohance Lifesciences Limited (BOM:543064)

Market Cap	274.37B
Revenue (ttm)	10.48B
Net Income (ttm)	2.79B
Shares Out	n/a
EPS (ttm)	10.93
PE Ratio	98.26
Forward PE	38.98
Dividend	n/a
Ex-Dividend Date	n/a

Volume	3,994
Average Volume	4,892
Open	1,195.00
Previous Close	1,204.95
Day's Range	1,138.65 - 1,206.05
52-Week Range	597.00 - 1,359.00
Beta	n/a
RSI	41.62
Earnings Date	May 28, 2025

About Cohance Lifesciences

Cohance Lifesciences Limited engage in the end-to-end contract development and manufacturing of intermediates and active pharmaceutical ingredients in India. The coampny offers active pharmaceutical ingredients and formulations for various applications; CDMO services, a flexible and custom solutions for challenging development and manufacturing needs; and clinical, analytical, and research services. It also manufactures finished dosage formulations for pharmaceutical companies; and specialty chemicals, such as electronic chemicals. The company ...

• Industry: Pharmaceutical Preparations
• Founded: 1989
• Employees: 1,193
• Stock Exchange: Bombay Stock Exchange
• Ticker Symbol: 543064

Financial Performance

In 2023, Suven Pharmaceuticals's revenue was 10.51 billion, a decrease of -21.56% compared to the previous year's 13.40 billion. Earnings were 3.00 billion, a decrease of -26.99%.